Progestogen-releasing intrauterine systems versus other forms of reversible contraceptives for contraception

French, Rebecca; Sorhaindo, Annik; Vliet, Huib AAM Van; Mansour, Diana; Robinson, Alexandra; Logan, Stuart; Helmerhorst, Frans M.; Guillebaud, John; Cowan, Frances M

doi:10.1002/14651858.cd001776.pub2

Cited by 26 publications

(15 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Breast tenderness following the use of the levonorgestrelreleasing intrauterine device has been reported in 11 -36% of users (French et al 2010;Kittelsen and Istre 1998). In our study, de novo breast tenderness was reported in 20% of women, although 72% of those who complained of breast tenderness before treatment reported that it had improved or disappeared.…”

Section: Vaughan and P Byrnecontrasting

confidence: 42%

An evaluation of the simultaneous use of the levonorgestrel-releasing intrauterine device (LNG-IUS, Mirena®) combined with endometrial ablation in the management of menorrhagia

Vaughan¹,

Byrne²

2012

Journal of Obstetrics and Gynaecology

View full text Add to dashboard Cite

The objective of our study was to document the efficacy and possible complications in women who were treated for menorrhagia with the simultaneous use of endometrial ablation and the levonorgestrel-releasing intrauterine device. Women were offered this combined treatment if they complained of menorrhagia and needed contraception. A structured questionnaire was mailed to 150 women who had undergone this combined treatment; 105 (70%) returned a completed questionnaire. The mean duration of follow-up was 25 months (range 6-54 months). Following treatment, 53 women (50.5%) described their periods as being lighter than normal and 49 (46%) had become amenorrhoeic. Overall, 101 (96%) stated that they were satisfied with the treatment. Of the women, 95 (90.5%) said that the treatment had been a 'complete success'; eight (7.6%) 'partly successful' and two women (1.9%) said the treatment had been a 'failure'. One woman subsequently required a hysterectomy. This observational study supports the hypothesis that combined endometrial ablation and insertion of a levonorgestrel-releasing intrauterine device is an effective treatment for menorrhagia and has some advantages when compared with the individual use of these treatments.

show abstract

Section: Vaughan and P Byrnecontrasting

confidence: 42%

An evaluation of the simultaneous use of the levonorgestrel-releasing intrauterine device (LNG-IUS, Mirena®) combined with endometrial ablation in the management of menorrhagia

Vaughan¹,

Byrne²

2012

Journal of Obstetrics and Gynaecology

View full text Add to dashboard Cite

show abstract

“…The copper IUD has a reported failure rate at 1 year of 0.8%, and a 10-year failure rate comparable to female sterilization of 1.9 per 100 12. A Cochrane Review evaluating 21 randomized trials concluded that the effectiveness of the LNG-20 IUD is similar to the copper IUD;13 other studies have shown the LNG-20 IUD to be among the most effective contraceptive methods, with a failure rate of 0.1% at 1 year and 0.5% at 5 years, similar to or better than female sterilization 14. Clinical trials of the LNG-14 IUD yielded similar results, showing a cumulative pregnancy rate of 0.9% over 3 years 15…”

Section: Efficacymentioning

confidence: 99%

Understanding benefits and addressing misperceptions and barriers to intrauterine device access among populations in the United States

Yoost¹

2014

PPA

View full text Add to dashboard Cite

Three intrauterine devices (IUDs), one copper and two containing the progestin levonorgestrel, are available for use in the United States. IUDs offer higher rates of contraceptive efficacy than nonlong-acting methods, and several studies have demonstrated higher satisfaction rates and continuation rates of any birth control method. This efficacy is not affected by age or parity. The safety of IUDs is well studied, and the risks of pelvic inflammatory disease, perforation, expulsion, and ectopic pregnancy are all of very low incidence. Noncontraceptive benefits include decreased menstrual blood loss, improved dysmenorrhea, improved pelvic pain associated with endometriosis, and protection of the endometrium from hyperplasia. The use of IUDs is accepted in patients with multiple medical problems who may have contraindications to other birth control methods. Yet despite well-published data, concerns and misperceptions still persist, especially among younger populations and nulliparous women. Medical governing bodies advocate for use of IUDs in these populations, as safety and efficacy is unchanged, and IUDs have been shown to decrease unintended pregnancies. Dispersion of accurate information among patients and practitioners is needed to further increase the acceptability and use of IUDs.

show abstract

“…However, according to two Cochrane Reviews, few studies have been published on this topic (10, 11). Furthermore, those that have been published found conflicting results.…”

Section: Introductionmentioning

confidence: 99%

Complications and Continuation of Intrauterine Device Use Among Commercially Insured Teenagers

Berenson

Tan

Hirth

et al. 2013

Obstetrics &Amp; Gynecology

View full text Add to dashboard Cite

Objective Many U.S. providers remain reluctant to prescribe intrauterine devices (IUDs) to teenagers due to concerns about serious complications. This study examined whether 15–19 year-old IUD users were more likely to experience complications, failure, or early discontinuation than adult users aged 20–24 and 25–44 years and whether there were differences in between users of levonorgestrel-releasing intrauterine systems and copper IUDs. Methods A retrospective cohort study was conducted using health insurance claims obtained from a private insurance company of 90,489 women who had an IUD inserted between 2002 and 2009. Logistic regression models were used to estimate the odds of experiencing complications, method failure, or early discontinuation within 12 months of insertion by age group and type of IUD inserted. Results Serious complications, including ectopic pregnancy and pelvic inflammatory disease, occurred in less than 1% of patients regardless of age or IUD type. Women aged 15–19 years were more likely than those aged 25–44 years to have a claim for dysmenorrhea OR=1.4, CI=1.1, 1.6), amenorrhea (OR=1.3, CI=1.1, 1.5), or normal pregnancy (OR=1.4, CI=1.1, 1.8). Overall, early discontinuation did not differ between teenagers and women aged 25–44 years (13% vs. 11%, p>.05). However, use of the levonorgestrel-releasing intrauterine system was associated with fewer complications and less early discontinuation than the copper IUD in all age groups. Conclusions The IUD is as appropriate for teenagers to use as it is for older women, with serious complications occurring infrequently in all groups. The levonorgestrel-releasing intrauterine system may be a better choice than copper IUD due to lower odds of complications, discontinuation, and failure.

show abstract

Progestogen-releasing intrauterine systems versus other forms of reversible contraceptives for contraception

Abstract: Progestogen-releasing intrauterine systems versus other forms of reversible contraceptives for contraception.

Cited by 26 publications

References 60 publications

An evaluation of the simultaneous use of the levonorgestrel-releasing intrauterine device (LNG-IUS, Mirena®) combined with endometrial ablation in the management of menorrhagia

An evaluation of the simultaneous use of the levonorgestrel-releasing intrauterine device (LNG-IUS, Mirena®) combined with endometrial ablation in the management of menorrhagia

Understanding benefits and addressing misperceptions and barriers to intrauterine device access among populations in the United States

Complications and Continuation of Intrauterine Device Use Among Commercially Insured Teenagers

Contact Info

Product

Resources

About